Richard William Scalzo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Richard william scalzo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Richard William Scalzo Today - Breaking & Trending Today

Dyne Therapeutics (NASDAQ:DYN) Trading Down 3.2%

Dyne Therapeutics (NASDAQ:DYN) Trading Down 3.2%
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United States , Stifel Nicolaus , Piper Sandler , Richard William Scalzo , Wildon Farwell , Dyne Therapeutics Company Profile , Morgan Stanley , Dyne Therapeutics Inc , Securities Exchange Commission , Janus Henderson Group , First Light Asset Management , Pricet Rowe Associates Inc , Dyne Therapeutics , Get Free Report , Therapeutics Stock Down , William Scalzo , Exchange Commission , State Teachers Retirement System , Henderson Group , Light Asset Management , Pricet Rowe Associates , Dyne Therapeutics Daily ,

Dyne Therapeutics (NASDAQ:DYN) Given Outperform Rating at Oppenheimer

Dyne Therapeutics (NASDAQ:DYN) Given Outperform Rating at Oppenheimer
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United States , Jasonp Rhodes , Richard William Scalzo , Stifel Nicolaus , Zurcher Kantonalbank Zurich Cantonalbank , Piper Sandler , Securities Exchange Commission , Principal Financial Group Inc , Allspring Global Investments Holdings , Dyne Therapeutics Inc , Morgan Stanley , China Universal Asset Management Co , Wetzel Investment Advisors Inc , Dyne Therapeutics , Free Report , Moderate Buy , Get Free Report , Director Jason , Exchange Commission , William Scalzo , Investment Advisors , Kantonalbank Zurich Cantonalbank , Global Investments Holdings , Universal Asset Management , Principal Financial Group , Financial Group ,

Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $36.20 Consensus Target Price from Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among […] ....

United States , Stifel Nicolaus , Piper Sandler , Richard William Scalzo , Raymond James , Venture Fund Xilp Atlas , Dyne Therapeutics Inc , Swiss National Bank , Metlife Investment Management , Dimensional Fund Advisors , Charles Schwab Investment Management Inc , Dyne Therapeutics , Get Free Report , National Bank , Life Investment Management , Fund Advisors , Schwab Investment Management , Get Free , Dyne Therapeutics Daily ,

Dyne Therapeutics (NASDAQ:DYN) Price Target Raised to $31.00

Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price objective increased by Chardan Capital from $20.00 to $31.00 in a research report sent to investors on Friday morning, Stock Target Advisor reports. Chardan Capital currently has a buy rating on the stock. Several other equities research analysts have also recently issued reports on the stock. […] ....

United States , Stifel Nicolaus , Zurcher Kantonalbank Zurich Cantonalbank , Piper Sandler , Dirk Kersten , Richard William Scalzo , Dyne Therapeutics Inc , Sphera Funds Management , Allspring Global Investments Holdings , Securities Exchange Commission , Royal Bank , Ameritas Investment Partners Inc , Dyne Therapeutics , Free Report , Chardan Capital , Stock Target Advisor , Moderate Buy , Get Free Report , Director Dirk Kersten , Exchange Commission , William Scalzo , Investment Partners , Kantonalbank Zurich Cantonalbank , Global Investments Holdings , Dyne Therapeutics Daily , Nasdaq Dyn ,

Dyne Therapeutics' (DYN) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $36.00 target price on the stock. HC Wainwright also issued estimates for Dyne Therapeutics’ Q1 2024 earnings at ($0.83) EPS, Q2 2024 earnings at ($0.83) […] ....

United States , Stifel Nicolaus , Piper Sandler , Wildon Farwell , Raymond James , Richard William Scalzo , Fcpm Iii Services , Dyne Therapeutics Company Profile , Dyne Therapeutics Inc , Vr Adviser , Frazier Life Sciences Management , Dyne Therapeutics , Free Report , Moderate Buy , Therapeutics Stock Down , Get Free Report , Street Corp , Commodore Capital , Dyne Therapeutics Daily ,